6GKU

Structure of galectin-10 in complex with the Fab fragment of a Charcot-Leyden crystal solubilizing antibody, 6F5

6GKU の概要

• エントリーDOI: 10.2210/pdb6gku/pdb
• 関連するPDBエントリー: 6GKQ 6GKS 6GKT
• 分子名称: Galectin-10, Fab 6F5 - Heavy Chain, Fab 6F5 - Light chain, ... (6 entities in total)
• 機能のキーワード: non-autocrystallizing, mutant, galectin-10, sugar binding protein
• 由来する生物種: Homo sapiens (Human); 詳細
• タンパク質・核酸の鎖数: 3
• 化学式量合計: 67953.83

構造登録者

Verstraete, K.,Verschueren, K.,Savvides, S.N. (登録日: 2018-05-21, 公開日: 2019-06-05, 最終更新日: 2024-10-23)

主引用文献

Persson, E.K.,Verstraete, K.,Heyndrickx, I.,Gevaert, E.,Aegerter, H.,Percier, J.M.,Deswarte, K.,Verschueren, K.H.G.,Dansercoer, A.,Gras, D.,Chanez, P.,Bachert, C.,Goncalves, A.,Van Gorp, H.,De Haard, H.,Blanchetot, C.,Saunders, M.,Hammad, H.,Savvides, S.N.,Lambrecht, B.N.
Protein crystallization promotes type 2 immunity and is reversible by antibody treatment.
Science, 364:-, 2019

PubMed Abstract: Although spontaneous protein crystallization is a rare event in vivo, Charcot-Leyden crystals (CLCs) consisting of galectin-10 (Gal10) protein are frequently observed in eosinophilic diseases, such as asthma. We found that CLCs derived from patients showed crystal packing and Gal10 structure identical to those of Gal10 crystals grown in vitro. When administered to the airways, crystalline Gal10 stimulated innate and adaptive immunity and acted as a type 2 adjuvant. By contrast, a soluble Gal10 mutein was inert. Antibodies directed against key epitopes of the CLC crystallization interface dissolved preexisting CLCs in patient-derived mucus within hours and reversed crystal-driven inflammation, goblet-cell metaplasia, immunoglobulin E (IgE) synthesis, and bronchial hyperreactivity (BHR) in a humanized mouse model of asthma. Thus, protein crystals may promote hallmark features of asthma and are targetable by crystal-dissolving antibodies.

PubMed: 31123109
DOI: 10.1126/science.aaw4295

実験手法

X-RAY DIFFRACTION (1.91 Å)